OncoSil Medical Limited (ASX:OSL)
Australia · Delayed Price · Currency is AUD 1.175
+0.025 (2.17%)
Aug 28, 2026, 3:48 PM AEST
OncoSil Medical Income Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Operating Revenue | 1.68 | 1.17 | 0.52 | 0.37 | 0.23 |
Other Revenue | 3.54 | 0.36 | 1.05 | 1.1 | 0.83 |
| 5.23 | 1.54 | 1.57 | 1.47 | 1.06 | |
Revenue Growth | 240.57% | -1.92% | 6.68% | 38.00% | -18.09% |
Cost of Revenue | 2.36 | 2.25 | 1.51 | 1.59 | 0.97 |
Gross Profit | 2.87 | -0.72 | 0.06 | -0.12 | 0.09 |
Selling, General & Admin | 7.77 | 10.16 | 9.05 | 8.36 | 8.29 |
Research & Development | 5.47 | 4.21 | 2.99 | 2.85 | 2.38 |
Operating Expenses | 13.74 | 14.37 | 12.04 | 11.21 | 10.67 |
Operating Income | -10.87 | -15.09 | -11.98 | -11.34 | -10.58 |
Interest Expense | -0.02 | -0 | -0 | -0.01 | -0.02 |
Interest & Investment Income | - | 0.09 | 0.07 | 0.06 | 0.01 |
Currency Exchange Gain (Loss) | 0.03 | -0.1 | 0.01 | -0.06 | -0.14 |
EBT Excluding Unusual Items | -10.86 | -15.1 | -11.91 | -11.34 | -10.73 |
Pretax Income | -10.86 | -15.1 | -11.91 | -11.34 | -10.73 |
Net Income | -10.86 | -15.1 | -11.91 | -11.34 | -10.73 |
Net Income to Common | -10.86 | -15.1 | -11.91 | -11.34 | -10.73 |
Net Income Growth | - | - | - | - | - |
Shares Outstanding (Basic) | 23 | 11 | 6 | 3 | 2 |
Shares Outstanding (Diluted) | 23 | 11 | 6 | 3 | 2 |
Shares Change | 107.25% | 97.77% | 95.67% | 39.32% | -0.89% |
EPS (Basic) | -0.48 | -1.38 | -2.16 | -4.02 | -5.29 |
EPS (Diluted) | -0.48 | -1.38 | -2.16 | -4.02 | -5.29 |
EPS Growth | - | - | - | - | - |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Free Cash Flow | -10.47 | -12.08 | -11.02 | -11.37 | -10.12 |
Free Cash Flow Per Share | -0.46 | -1.10 | -2.00 | -4.03 | -4.99 |
Gross Margin | 54.92% | -46.79% | 3.55% | -8.27% | 8.55% |
Operating Margin | -207.96% | -982.80% | -765.58% | -772.48% | -994.72% |
Profit Margin | -207.70% | -983.53% | -761.07% | -772.98% | -1008.73% |
Free Cash Flow Margin | -200.32% | -786.66% | -704.07% | -775.06% | -951.30% |
EBITDA | -10.81 | -15.08 | -11.98 | -11.32 | -10.55 |
EBITDA Margin | -206.82% | - | - | - | - |
D&A For EBITDA | 0.06 | 0.01 | 0.01 | 0.02 | 0.03 |
EBIT | -10.87 | -15.09 | -11.98 | -11.34 | -10.58 |
EBIT Margin | -207.96% | - | - | - | - |